ClinicalTrials.gg
Status unknownNCT03427853Updated Feb 9, 2018

A Study to Evaluate the Denosumab in Healthy Adults

A Phase 1 interventional study of LY06006 and Placebos in Healthy Adults, sponsored by Luye Pharma Group Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-09.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to healthy adults in China

Read the detailed description

This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation Phase I study in healthy adults in China, conducted in one center.

The objectives are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection (code name:LY06006).

Subjects would be sequentially enrolled in one of three cohorts. Eight subjects in the first cohort would receive a single 18 mg subcutaneous injection of LY06006. If the safety and tolerability were confirmed at Day 56, the other 16 subjects would be enrolled in the second cohort to receive a single 60 mg subcutaneous injection of LY06006. If the safety and tolerability were confirmed at Day 56 in 60-mg group, the last 8 subjects would be enrolled in the third cohort to receive a single 120 mg subcutaneous injection of LY06006.

02

Conditions studied

  • Healthy Adults
03

In context

Lead sponsor

Luye Pharma Group Ltd. is the lead sponsor of 74 studies on the registry; 15 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ICF and complied with ICF requirement and restrictions
  • Healthy male and female, 18≤age≤65
  • In screening visit, male body weight≥50kg,female body weight≥45kg,and 19.0≤≤24.0 kg/m2;
  • At screening visit: physical examination, vital signs, laboratory tests, , chest X-ray examination, abdominal CT examination are normal or abnormal but no clinical significance confirmed by investigators;
  • During the study period and within 12 months after the study drug administration, the subjects and partners agreed to use reliable measures

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Fertility plan within one year;
  • The subject has a history of or allergy to LY06006 or any of its ;or allergy to any drug, food and pollen, or IGE test is positive.
  • Subjects are suffering from or have had osteomyelitis or osteonecrosis of the Jaw, or plan to have invasive dental or maxillofacial surgery during the study, or dental or oral surgery wounds unhealed;
  • Have fractures in past six months;
  • Active respiratory, digestive, urinary, reproductive or skin infections;
  • Have oncology family history ;
  • Have mental illness history;
  • In screening visit: Chest X-ray, abdominal CT indicated clinical significance,for example: tuberculosis, inflammation, et al;
  • PPD test positive with 48-72 hrs induration reading≥5mm;
  • Blood chemistry: or AST >1.5 ,Cr>1.0 ULN;Blood routine:WBC\<0.8 LLN or>1.2 ULN;NE\<0.8 LLN;\<0.8 LLN;HGB\<0.8LLN;
  • Suffering from or have had the following diseases affecting the bone metabolism: malignant tumors (including myeloma), hypoparathyroidism / hyperthyroidism, hypothyroidism, acromegaly, cushing's syndrome, hypopituitarism, severe , rheumatoid arthritis, osteomalacia et al;
  • The medicines that may affect bone turnover are used before randomization or planned to use in the study period , including but not limited : denosumab, bisphosphonates or fluorides were used in past 12 months; with hormone,hormone replacement therapy(tibolone、hormone、selective estrogen receptor modulators)aromatase inhibitors, calcitonin, strontium salt, parathyroid hormone (or derivative), vitamin D supplement,anabolic steroids, systemic , calcitriol or analogues, diuretics, anticonvulsant drugs;inhalation or local use of glucocorticoids within 2 weeks
  • Significant changes in physical activity in 6 months before randomization; or have been playing strenuous sports, or plan to play strenuous sports during the study period.
  • Any of , -Ab, Anti-, TP-Ab is positive;
  • Hypocalcemia or hypercalcemia,or serum calcium calibrated by serum albumin is not within the normal range
  • The average daily smoking amount is more than 5 cigarettes per day during three months before randomization, or smoking can't be prohibited during the study period;
  • Alcohol abuse or drank more than 28 units / week of alcohol((1 unit =350ml beer, 45ml spirits or 150ml Wine), or alcohol breath test is positive;
  • History of drug dependency or drug abuse, or urine drug screening test is positive;
  • Donated whole blood, blood component, or massive hemorrhage (>400ml)three months before randomization.
  • Use of any vaccines in 6 months of initiation of study therapy
  • participation in another clinical trial within 3 months prior to enrollment
  • Had Blood faint and acupuncture syncope history;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    LY06006

    LY06006 18mg, 60mg 120mg subcutaneous injection

    Drug: LY06006

  • Placebo comparator
    Placebo

    Placebo subcutaneous injection

    Drug: Placebos

Interventions

  • LY06006 18mg, 60mg, 120mg subcutaneous injection

  • DrugPlacebos

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment related adverse events

    Number of patients with treatment related adverse events assessed by change from baseline

    Time frame: 56 days

  2. Number of patients with abnormal laboratory values

    Number of patients with abnormal laboratory values assessed by change from baseline

    Time frame: 56 days

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: 56 days

  2. Area under the Curve (AUC)

    Time frame: 56 days

  3. Number of patients with anti drug antibodies

    Time frame: 56 days

07

Study locations

1 of 1 sites recruiting
  • Peking University People's Hospital
    Beijing, Xicheng District, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Dec 2019, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 9, 2018
StartActual
Jan 10, 2018
Primary completionEst.
Dec 28, 2019
CompletionEst.
Dec 28, 2019
Last update
Feb 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03427853
Responsible party
Sponsor
First posted
Feb 9, 2018
Start date
Jan 10, 2018
Primary completion
Dec 28, 2019 (estimated)
Completion
Dec 28, 2019 (estimated)
Last update
Feb 9, 2018

Study contacts

Yi Fang, MD
Contact
fygk7000@163.com
8610-8832666
Huanhuan Jiang
study director · Shangdon Boan Biotechnology Co Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY06006

Start the discussion